195 related articles for article (PubMed ID: 16367909)
1. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
3. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.
Kirk CJ; Hartigan-O'Connor D; Nickoloff BJ; Chamberlain JS; Giedlin M; Aukerman L; Mule JJ
Cancer Res; 2001 Mar; 61(5):2062-70. PubMed ID: 11280767
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT.
Hisada M; Yoshimoto T; Kamiya S; Magami Y; Miyaji H; Yoneto T; Tamada K; Aoki T; Koyanagi Y; Mizuguchi J
Cancer Gene Ther; 2004 Apr; 11(4):280-8. PubMed ID: 15002032
[TBL] [Abstract][Full Text] [Related]
5. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
6. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination.
Matsuyoshi H; Senju S; Hirata S; Yoshitake Y; Uemura Y; Nishimura Y
J Immunol; 2004 Jan; 172(2):776-86. PubMed ID: 14707047
[TBL] [Abstract][Full Text] [Related]
7. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
8. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma.
Sharma S; Stolina M; Zhu L; Lin Y; Batra R; Huang M; Strieter R; Dubinett SM
Cancer Res; 2001 Sep; 61(17):6406-12. PubMed ID: 11522634
[TBL] [Abstract][Full Text] [Related]
9. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K
Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616
[TBL] [Abstract][Full Text] [Related]
10. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
[TBL] [Abstract][Full Text] [Related]
11. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
Zhang W; He L; Cao X
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
[TBL] [Abstract][Full Text] [Related]
12. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
[TBL] [Abstract][Full Text] [Related]
13. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.
Tolba KA; Bowers WJ; Muller J; Housekneckt V; Giuliano RE; Federoff HJ; Rosenblatt JD
Cancer Res; 2002 Nov; 62(22):6545-51. PubMed ID: 12438249
[TBL] [Abstract][Full Text] [Related]
14. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.
Fujii S; Shimizu K; Kronenberg M; Steinman RM
Nat Immunol; 2002 Sep; 3(9):867-74. PubMed ID: 12154358
[TBL] [Abstract][Full Text] [Related]
15. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells.
Carnaud C; Lee D; Donnars O; Park SH; Beavis A; Koezuka Y; Bendelac A
J Immunol; 1999 Nov; 163(9):4647-50. PubMed ID: 10528160
[TBL] [Abstract][Full Text] [Related]
16. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
17. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
Krishnan L; Sad S; Patel GB; Sprott GD
Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Matsuura I; Noguchi K; Yamaue H
Clin Cancer Res; 2002 Aug; 8(8):2742-9. PubMed ID: 12171908
[TBL] [Abstract][Full Text] [Related]
19. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide.
Toura I; Kawano T; Akutsu Y; Nakayama T; Ochiai T; Taniguchi M
J Immunol; 1999 Sep; 163(5):2387-91. PubMed ID: 10452972
[TBL] [Abstract][Full Text] [Related]
20. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
